Cabaletta Bio
Clinical trials sponsored by Cabaletta Bio, explained in plain language.
A clinical-stage biotechnology company developing CAR T cell therapies for autoimmune diseases.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Engineered immune cells take on rare Muscle-Weakening disease
Disease control Recruiting nowThis early-stage study tests a new treatment called CABA-201 for people with generalized myasthenia gravis, a condition that causes severe muscle weakness. The therapy uses a patient's own immune cells, modified to target and destroy faulty immune cells that attack the body. The …
Phase: PHASE1, PHASE2 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Engineered immune cells take on muscle disease
Disease control Recruiting nowThis study tests a one-time treatment called CABA-201, made from a patient's own immune cells, for people with active inflammatory muscle diseases like dermatomyositis. The therapy aims to reset the immune system by targeting and removing certain immune cells. Researchers will ch…
Phase: PHASE2, PHASE3 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Could CAR t cells tame scleroderma? new trial launches
Disease control Recruiting nowThis early-stage study tests a new treatment called CABA-201 for people with systemic sclerosis (scleroderma), a disease that causes hardening of the skin and can damage organs. The treatment uses a patient's own immune cells, modified to target and destroy faulty B cells that dr…
Phase: PHASE1, PHASE2 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Immune cell therapy takes on rare blistering skin disease
Disease control Recruiting nowThis study tests two types of engineered immune cells (CAR T cells) in 40 adults with active pemphigus vulgaris, a painful blistering skin condition. The cells are designed to target and reduce the faulty immune cells that attack the skin. The main goal is to check safety and fin…
Phase: PHASE1, PHASE2 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Could a single infusion of modified immune cells tame lupus?
Disease control Recruiting nowThis early-stage trial is testing a treatment called CABA-201 for people with active systemic lupus erythematosus (SLE), including those with lupus nephritis. CABA-201 is made from a patient's own immune cells, which are modified to target and temporarily remove B cells—a key dri…
Phase: PHASE1, PHASE2 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC